D. S. Ettinger, Overview and state of the art in the management of lung cancer, Oncol. Williston Park N, vol.18, pp.3-9, 2004.

R. C. Lilenbaum, Single-Agent Versus Combination Chemotherapy in Advanced Non???Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730), Journal of Clinical Oncology, vol.23, issue.1, pp.190-196, 2005.
DOI : 10.1200/JCO.2005.07.172

R. E. Favoni and A. Alama, Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout, Drug Discovery Today, vol.18, issue.1-2, pp.11-24, 2013.
DOI : 10.1016/j.drudis.2012.07.011

A. Mogi and H. Kuwano, TP53 Mutations in Nonsmall Cell Lung Cancer, Journal of Biomedicine and Biotechnology, vol.9, issue.3, p.583929, 2011.
DOI : 10.1038/nrd2656

K. G. Wiman, Pharmacological reactivation of mutant p53: from protein structure to the cancer patient, Oncogene, vol.30, issue.30, pp.4245-4252, 2010.
DOI : 10.1038/onc.2010.188

B. P. Bouchet, C. Caron-de-fromentel, A. Puisieux, and C. M. Galmarini, p53 as a target for anti-cancer drug development, Critical Reviews in Oncology/Hematology, vol.58, issue.3, pp.190-207, 2006.
DOI : 10.1016/j.critrevonc.2005.10.005

W. Wang and W. S. El-deiry, Restoration of p53 to limit tumor growth, Current Opinion in Oncology, vol.20, issue.1, pp.90-96, 2008.
DOI : 10.1097/CCO.0b013e3282f31d6f

M. Athar, C. A. Elmets, and L. Kopelovich, Pharmacological Activation of p53 in Cancer Cells, Current Pharmaceutical Design, vol.17, issue.6, pp.631-639, 2011.
DOI : 10.2174/138161211795222595

V. J. Bykov, Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound, Nature Medicine, vol.8, issue.3, pp.282-288, 2002.
DOI : 10.1038/nm0302-282

J. M. Lambert, A. Moshfegh, P. Hainaut, K. G. Wiman, and V. J. Bykov, Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis, Oncogene, vol.30, issue.9, pp.1329-1338, 2010.
DOI : 10.1016/S0092-8674(01)00611-0

V. J. Bykov, N. Issaeva, G. Selivanova, and K. G. Wiman, Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database, Carcinogenesis, vol.23, issue.12, pp.2011-2018, 2002.
DOI : 10.1093/carcin/23.12.2011

N. Zache, J. M. Lambert, K. G. Wiman, and V. J. Bykov, PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53, Cell. Oncol. Off. J. Int. Soc. Cell. Oncol, vol.30, pp.411-418, 2008.

M. Farnebo, V. J. Bykov, and K. G. Wiman, The p53 tumor suppressor: A master regulator of diverse cellular processes and therapeutic target in cancer, Biochemical and Biophysical Research Communications, vol.396, issue.1, pp.85-89, 2010.
DOI : 10.1016/j.bbrc.2010.02.152

D. Moreau, Original triazine inductor of new specific molecular targets, with antitumor activity against nonsmall cell lung cancer, International Journal of Cancer, vol.48, issue.11, pp.2676-2683, 2008.
DOI : 10.1002/ijc.23809

C. Jacquot, Proliferation arrest in G1 phase of a non-small cell lung cancer cell line (NSCLC-N6) treated by an original compound methyl-4-methoxy-3-(3-methyl-2-butanoyl) benzoate (VT1) independently of the p53/p21 cascade, International Journal of Oncology, vol.23, pp.495-501, 2003.
DOI : 10.3892/ijo.23.2.495

S. F. Law, Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae., Molecular and Cellular Biology, vol.16, issue.7, pp.3327-3337, 1996.
DOI : 10.1128/MCB.16.7.3327

S. F. Law, G. M. O-'neill, S. J. Fashena, M. B. Einarson, and E. A. Golemis, The Docking Protein HEF1 Is an Apoptotic Mediator at Focal Adhesion Sites, Molecular and Cellular Biology, vol.20, issue.14, pp.5184-5195, 2000.
DOI : 10.1128/MCB.20.14.5184-5195.2000

S. F. Law, Y. Z. Zhang, A. J. Klein-szanto, and E. A. Golemis, Cell Cycle-Regulated Processing of HEF1 to Multiple Protein Forms Differentially Targeted to Multiple Subcellular Compartments, Molecular and Cellular Biology, vol.18, issue.6, pp.3540-3551, 1998.
DOI : 10.1128/MCB.18.6.3540

C. Roussakis, Study of in vitro drug sensitivity on a newly established cell line from a primary bronchial epidermoid carcinoma of human origin (NSCLCN6), Anticancer Res, vol.11, pp.2239-2244, 1991.

T. Soussi and G. Lozano, p53 mutation heterogeneity in cancer, Biochemical and Biophysical Research Communications, vol.331, issue.3, pp.834-842, 2005.
DOI : 10.1016/j.bbrc.2005.03.190

E. Brambilla and C. Brambilla, p53 and lung cancer, Pathol. Biol. (Paris), vol.45, pp.852-863, 1997.

M. Malleter, A novel large regulator RNA, B2, partially overlaps the HEF1/NEDD9/Cas-L gene, Int. J. Mol. Med, vol.25, pp.897-903, 2010.

O. Neill, G. M. Seo, S. Serebriiskii, I. G. Lessin, S. R. Golemis et al., A New Central Scaffold for Metastasis: Parsing HEF1/Cas-L/NEDD9, Cancer Research, vol.67, issue.19, pp.8975-8979, 2007.
DOI : 10.1158/0008-5472.CAN-07-1328

E. N. Pugacheva and E. A. Golemis, HEF1-Aurora A Interactions: Points of Dialog between the Cell Cycle and Cell Attachment Signaling Networks, Cell Cycle, vol.5, issue.4, pp.384-391, 2006.
DOI : 10.4161/cc.5.4.2439

Y. Feng, The CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss, Cancer Research, vol.72, issue.24, pp.6502-6511, 2012.
DOI : 10.1158/0008-5472.CAN-12-1909

H. Ji, LKB1 modulates lung cancer differentiation and metastasis, Nature, vol.41, issue.7155, pp.807-810, 2007.
DOI : 10.1093/bioinformatics/19.2.185

M. G. Ormerod, M. K. Collins, G. Rodriguez-tarduchy, and D. Robertson, Apoptosis in interleukin-3-dependent haemopoietic cells, Journal of Immunological Methods, vol.153, issue.1-2, pp.57-65, 1992.
DOI : 10.1016/0022-1759(92)90305-D

S. Fournel, Apoptosis without decrease of cell DNA content, FEBS Letters, vol.207, issue.2, pp.188-192, 1995.
DOI : 10.1016/0014-5793(95)00532-E

G. Selivanova and K. G. Wiman, Reactivation of mutant p53: molecular mechanisms and therapeutic potential, Oncogene, vol.13, issue.15, pp.2243-2254, 2007.
DOI : 10.2174/1389557033488178

J. M. Lambert, PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain, Cancer Cell, vol.15, issue.5, pp.376-388, 2009.
DOI : 10.1016/j.ccr.2009.03.003

D. J. Giard, In Vitro Cultivation of Human Tumors: Establishment of Cell Lines Derived From a Series of Solid Tumors 2, JNCI: Journal of the National Cancer Institute, vol.51, issue.5, pp.1417-1423, 1973.
DOI : 10.1093/jnci/51.5.1417

K. E. Sawin and S. A. Endow, Meiosis, mitosis and microtubule motors, BioEssays, vol.62, issue.6, pp.399-407, 1993.
DOI : 10.1002/bies.950150606

K. Suzuki and K. Takahashi, Reduced cell adhesion during mitosis by threonine phosphorylation of ?1 integrin, Journal of Cellular Physiology, vol.20, issue.2, pp.297-305, 2003.
DOI : 10.1002/jcp.10354

L. L. Vindelov, Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions. A new method for rapid isolation and straining of nuclei, Virchows Arch. B Cell Pathol, vol.24, pp.227-242, 1977.